Stroke and Thromboembolism in Atrial Fibrillation - Systematic Review of Stroke Risk Factors and Risk Stratification Schema -

被引:123
作者
Pisters, Ron [1 ,2 ]
Lane, Deirdre A. [1 ]
Marin, Francisco [3 ]
Camm, A. John [4 ]
Lip, Gregory Y. H. [1 ]
机构
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
[2] Maastricht Univ, Med Ctr, Dept Cardiol, Maastricht, Netherlands
[3] Univ Murcia, Hosp Univ Virgen Arrixaca, Dept Cardiol, Murcia, Spain
[4] St Georges Univ London, Div Clin Sci, London, England
关键词
Atrial fibrillation; Risk factors; Stroke prevention; TRANSIENT ISCHEMIC ATTACK; HEART RHYTHM ASSOCIATION; COST-EFFECTIVENESS; PREDICTING STROKE; ANTITHROMBOTIC THERAPY; DABIGATRAN ETEXILATE; EUROPEAN-SOCIETY; PREVENT STROKE; TASK-FORCE; CARDIOLOGY COMMITTEE;
D O I
10.1253/circj.CJ-12-1036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We performed a systematic review of the available evidence on the relationship between the individual clinical, echocardiographic and laboratory characteristics of patients with atrial fibrillation (AF) and the risk of stroke. A systematic review was also performed of all published stroke risk stratification models, as well as the accuracy of their discriminative ability between risk strata. Third, we reviewed the literature on cost-effectiveness analyses with oral anticoagulation in AF. From the systematic review on stroke risk factors, a prior stroke or transient ischemic attack (15/16 studies positive, risk ratio [RR] 2.86), hypertension (11/20 studies positive, RR 2.27), aging (9/13 studies positive, RR 1.46 per decade increase), structural heart disease (9/13 studies positive, RR 2.0) and diabetes (9/14 studies positive, RR 1.62) were found to be good independent predictors of stroke. Supportive evidence was found for sex (8/22 studies positive, RR 1.67), vascular disease (6/17 studies positive, RR 2.61) and heart failure (7/18 studies positive, RR 1.85). The various risk stratification schemes classified variable proportions as low, moderate and high risk, but the CHA(2)DS(2)-VASc score classified the smallest proportion of patients as 'low risk'. Anticoagulation with vitamin K antagonists and dabigatran is cost-effective in patients at high risk of stroke, but not in patients without any other stroke risk factor beside AF. Continued efforts are warranted to improve the antithrombotic management of AF patients to identify, and challenge, risk factors and refine risk stratification models in order to realize an individualized tailored, risk factor-based approach. (Circ J 2012; 76: 2289-2304)
引用
收藏
页码:2289 / 2304
页数:16
相关论文
共 92 条
[1]   Atrial fibrillation and upper limb thromboembolectomy: a national cohort study [J].
Andersen, L. V. ;
Mortensen, L. S. ;
Lip, G. Y. H. ;
Lindholt, J. S. ;
Faergeman, O. ;
Henneberg, E. W. ;
Frost, L. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (09) :1738-1743
[2]   PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK [J].
ANDERSON, DC ;
ASINGER, RW ;
NEWBURG, SM ;
FARMER, CC ;
WANG, K ;
BUNDLIE, SR ;
KOLLER, RL ;
JAGIELLA, WM ;
KREHER, S ;
JORGENSEN, CR ;
SHARKEY, SW ;
FLAKER, GC ;
WEBEL, R ;
NOLTE, B ;
STEVENSON, P ;
BYER, J ;
WRIGHT, W ;
CHESEBRO, JH ;
WIEBERS, DO ;
HOLLAND, AE ;
MILLER, DM ;
BARDSLEY, WT ;
LITIN, SC ;
MEISSNER, I ;
ZERBE, DM ;
MCANULTY, JH ;
MARCHANT, C ;
COULL, BM ;
FELDMAN, G ;
HAYWARD, A ;
GANDARA, E ;
MACMILLAN, K ;
BLANK, N ;
LEONARD, AD ;
KANTER, MC ;
ISENSEE, LM ;
QUIROGA, ES ;
PRESTI, CH ;
TEGELER, CH ;
LOGAN, WR ;
HAMILTON, WP ;
GREEN, BJ ;
BACON, RS ;
REDD, RM ;
CADELL, DJ ;
GOMEZ, CR ;
JANOSIK, DL ;
LABOVITZ, AJ ;
KELLEY, RE ;
CHAHINE, R .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :1-5
[3]  
Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273
[4]  
ANDERSON DC, 1992, ANN INTERN MED, V116, P6
[5]   RISK-FACTORS FOR THROMBOEMBOLIC STROKE IN ELDERLY PATIENTS WITH CHRONIC ATRIAL-FIBRILLATION [J].
ARONOW, WS ;
GUTSTEIN, H ;
HSIEH, FY .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (05) :366-367
[6]   Risk factors for new thromboembolic stroke in patients ≥62 years of age with chronic atrial fibrillation [J].
Aronow, WS ;
Ahn, C ;
Kronzon, I ;
Gutstein, H .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (01) :119-121
[7]   Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study [J].
Banerjee, Amitava ;
Lane, Deirdre A. ;
Torp-Pedersen, Christian ;
Lip, Gregory Y. H. .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) :584-589
[8]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[9]   RISK FOR SYSTEMIC EMBOLIZATION OF ATRIAL-FIBRILLATION WITHOUT MITRAL-STENOSIS [J].
CABIN, HS ;
CLUBB, KS ;
HALL, C ;
PERLMUTTER, RA ;
FEINSTEIN, AR .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (16) :1112-1116
[10]  
Camm AJ, 2012, EUR HEART J, V33